Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 3

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

NCT ID: NCT05633654Sponsor: Gilead SciencesLast updated: 2026-06-10

Summary

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Arms & interventions

  • DrugSacituzumab govitecan-hziy (SG)

    Administered intravenously

  • DrugPembrolizumab

    Administered intravenously

  • DrugCapecitabine

    Tablets administered orally

Outcome measures

Primary

  • Invasive Disease-free Survival (iDFS)

    iDFS is defined as the time from the date of randomization to death from any cause or one of the following events (whichever occurs first): invasive local, regional, or distant recurrence, invasive contralateral breast cancer.

    Time frame: Up to 60 months

Secondary

  • Overall Survival (OS)

    Time frame: Up to 96 months

  • Distant Disease-free Survival (dDFS)

    Time frame: Up to 60 months

  • Recurrence-free Survival (RFS)

    Time frame: Up to 60 months

  • Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    Time frame: First dose date up to 38 months plus 30 days

  • Percentage of Participants Experiencing Laboratory Abnormalities

    Time frame: First dose date up to 38 months plus 30 days

  • Time to Worsening (TTW) of Quality of Life (QoL) Based on Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) Trial Outcome Index (TOI) Scores

    Time frame: Up to 60 months

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Key Inclusion Criteria: * Age \> 18 years, with residual invasive triple negative breast cancer (TNBC) in the breast or lymph nodes after neoadjuvant therapy and surgery: * TNBC criteria for the study is defined as estrogen receptor (ER) and progesterone receptor (PR) ≤ 10%, human epidermal growth factor receptor 2 (HER2)-negative per American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines (immunohistochemistry (IHC) and/or in situ hybridization (ISH)). * Adequate excision and surgical removal of all clinically evident of disease in the breast and/or lymph nodes and have adequately recovered from surgery. * Submission of both pre-neoadjuvant treatment diagnostic biopsy and resected residual invasive disease tissue. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Individuals must have received appropriate radiotherapy aligned with local/institutional practice and have recovered prior to starting study treatment. * Adequate organ function. Key Exclusion Criteria: * Stage IV (metastatic) breast cancer as well as history of any prior (ipsi- or contralateral) invasive breast cancer. * Prior treatment with another stimulatory or coinhibitory T-cell receptor agent (eg, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), OX-40, cluster of differentiation 137 (CD137), prior treatment with any HER2-directed agent, prior endocrine therapy for \> 4 weeks or planned concurrent endocrine therapy while receiving on-study treatment. * Evidence of recurrent disease following preoperative therapy and surgery. * Prior treatment with topoisomerase 1 inhibitors or antibody-drug conjugates (ADCs) containing a topoisomerase inhibitor. * Individuals with germline breast cancer gene (BRCA) mutations. * Myocardial infarction or unstable angina pectoris within 6 months of enrollment or history of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias or Left ventricular ejection fraction (LVEF) of \< 50% * Active serious infections requiring anti-microbial therapy. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study locations (184)

Alabama Oncology

Birmingham, Alabama, 35243

Recruiting

Clearview Cancer Institute

Huntsville, Alabama, 35805

Recruiting

Palo Verde Hematology Oncology

Glendale, Arizona, 85304

Recruiting

Mayo Clinic Hospital

Phoenix, Arizona, 85054

Withdrawn

Arizona Oncology Associates

Prescott Valley, Arizona, 86314

Withdrawn

Alta Bates Summit Medical Center

Berkeley, California, 94704

Recruiting

Community Cancer Institute

Clovis, California, 93611

Withdrawn

PIH Health Whittier Hospital

Downey, California, 90241

Recruiting

Compassionate Cancer Care Medical Group - Inc

Fountain Valley, California, 92708

Recruiting

Los Angeles Cancer Network

Los Angeles, California, 90017

Recruiting

USC Norris Comprehensive Cancer Center

Los Angeles, California, 90033

Withdrawn

Cedars-Sinai Cancer at Beverly Hills

Los Angeles, California, 90048

Recruiting

Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663

Recruiting

Emad Ibrahim, MD, INC

Redlands, California, 92373

Withdrawn

Sutter Institute for Medical Research

Sacramento, California, 95816

Recruiting

City of Hope (Duarte)

San Francisco, California, 94143

Recruiting

UCSF Medical Center

San Francisco, California, 94143

Recruiting

Sansum Clinic

Santa Barbara, California, 93105

Recruiting

Stockton Hematology Oncology Medical Group

Stockton, California, 95204

Recruiting

University of Colorado Cancer Center

Aurora, Colorado, 80045

Withdrawn

Norwalk Hospital

Danbury, Connecticut, 06810

Withdrawn

Stamford Hospital

Stamford, Connecticut, 06902

Recruiting

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007

Recruiting

MedStar Washington Hospital Center

Washington D.C., District of Columbia, 20010

Recruiting

Morton Plant Hospital - Bay Care

Clearwater, Florida, 00337

Withdrawn

University of Florida

Gainesville, Florida, 32610

Withdrawn

Mayo Clinic Florida

Jacksonville, Florida, 32224

Recruiting

Cancer Specialists of North Florida

Jacksonville, Florida, 32256

Recruiting

Jupiter Medical Center

Jupiter, Florida, 33458

Recruiting

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, 33140

Recruiting

Midland Florida Clinical Research Center, L

Orange City, Florida, 32763

Withdrawn

Orlando Health

Orlando, Florida, 32806

Active Not Recruiting

Cancer Care Centers of Brevard, Inc

Palm Bay, Florida, 32909

Recruiting

Memorial Healthcare System

Pembroke Pines, Florida, 33028

Recruiting

Sacred Heart Medical Oncology Group

Pensacola, Florida, 32504

Withdrawn

Sylvester Comprehensive Cancer Center

Plantation, Florida, 33324

Recruiting

Cleveland Clinic Florida, Martin North Hospital

Stuart, Florida, 34994

Withdrawn

St. Joseph's Hospital

Tampa, Florida, 33614

Withdrawn

Weston Hospital

Weston, Florida, 33331

Withdrawn

University Cancer & Blood Center, LLC.

Athens, Georgia, 30607

Recruiting

Piedmont Cancer Institute

Atlanta, Georgia, 30318

Recruiting

Northside Hospital

Atlanta, Georgia, 30342

Recruiting

Northwest Georgia Oncology Centers, PC

Marietta, Georgia, 30060

Recruiting

Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta

Newnan, Georgia, 30265

Recruiting

Pearlman Cancer Center

Valdosta, Georgia, 31602

Recruiting

St Lukes Mountain States Tumor Institute

Boise, Idaho, 83712

Withdrawn

Kootenai Health

Coeur d'Alene, Idaho, 83814

Recruiting

Northwestern Medicine

Chicago, Illinois, 60611

Recruiting

Rush University Medical Center

Chicago, Illinois, 60612

Recruiting

University of Illinois

Chicago, Illinois, 60612

Withdrawn

University of Chicago Medical Center

Chicago, Illinois, 60637

Recruiting

NorthShore University Healthsystem

Evanston, Illinois, 60201

Recruiting

Edward Hospital

Naperville, Illinois, 60540

Recruiting

West Suburban Medical Center- River Forest

River Forest, Illinois, 60305

Withdrawn

Edward H. Kaplan MD & Associates - Hematology/Oncology of the North Shore

Skokie, Illinois, 60076

Withdrawn

Springfield Clinic LLP

Springfield, Illinois, 62702

Withdrawn

Carle Cancer Center

Urbana, Illinois, 61801

Recruiting

Franciscan Health Indianapolis

Indianapolis, Indiana, 46237

Recruiting

Investigative Clinical Research of Indiana, LLC

Indianapolis, Indiana, 46260

Withdrawn

IU Health Arnett Hospital

Lafayette, Indiana, 47904

Withdrawn

Franciscan Health Munster

Munster, Indiana, 46321

Withdrawn

Mercy Medical Center

Cedar Rapids, Iowa, 52403

Withdrawn

Mission Cancer & Blood - John Stoddard Cancer Center

Des Moines, Iowa, 50309

Recruiting

University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242

Recruiting

Cancer Center of Kansas

Wichita, Kansas, 67214

Recruiting

University of Kentucky

Lexington, Kentucky, 40536

Withdrawn

Norton Healthcare, Inc.

Louisville, Kentucky, 40207

Recruiting

Mercy Health

Paducah, Kentucky, 42003

Recruiting

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, 70809

Recruiting

University Medical Center New Orleans

New Orleans, Louisiana, 70112

Withdrawn

New England Cancer Specialists

Scarborough, Maine, 04074

Recruiting

Sinai Hospital of Baltimore, Inc.

Baltimore, Maryland, 21215

Recruiting

St. Agnes Hospital

Baltimore, Maryland, 21229

Recruiting

Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231

Recruiting

American Oncology Partners of Maryland, PA

Bethesda, Maryland, 20817

Withdrawn

James M Stockman Cancer Institute

Frederick, Maryland, 21702

Recruiting

Greater Baltimore Medical Center

Towson, Maryland, 21204

Recruiting

Massachusetts General Hospital

Boston, Massachusetts, 02115

Recruiting

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215

Recruiting

Dana Farber Cancer Institute

Boston, Massachusetts, 02215

Recruiting

Dana-Farber Cancer Institute @Foxborough

Foxborough, Massachusetts, 02035

Recruiting

Dana-Farber Cancer Institude at Merrimack Valley

Methuen, Massachusetts, 01844

Recruiting

Dana Farber Cancer Institute @ Milford Regional Hospital

Milford, Massachusetts, 01757

Recruiting

Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital

South Weymouth, Massachusetts, 02190

Recruiting

Baystate Medical Center Inc.

Springfield, Massachusetts, 01199

Withdrawn

University of Massachusetts Worcester

Worcester, Massachusetts, 01655

Withdrawn

Henry Ford Health System

Detroit, Michigan, 48202

Withdrawn

Cancer and Hematology Centers of Western Michigan

Grand Rapids, Michigan, 49503

Recruiting

Ascension

Grosse Pointe Woods, Michigan, 48236

Withdrawn

William Beaumont Hospital

Royal Oak, Michigan, 48073

Recruiting

Ascension Providence Hospital Southfield Cancer Center

Southfield, Michigan, 48075

Withdrawn

Trinity Health St. Joseph Mercy Ann Arbor

Ypsilanti, Michigan, 48197

Withdrawn

Minnesota Oncology Hematology, PA

Maplewood, Minnesota, 55109

Recruiting

Virginia Piper Cancer Center (Allina Health)

Minneapolis, Minnesota, 55407

Recruiting

University of Minnesota Medical Center, Fairview

Minneapolis, Minnesota, 55455

Recruiting

Mayo Clinic Rochester

Rochester, Minnesota, 55905

Recruiting

Metro Minnesota Community Oncology

Saint Louis Park, Minnesota, 55426

Recruiting

Washington University School of Medicine

St Louis, Missouri, 63110

Recruiting

Baptist Clinical Research Institute

St Louis, Missouri, 63131

Recruiting

Mercy Hospital

St Louis, Missouri, 63141

Withdrawn

Mary Lanning Healthcare - Morrison Cancer Center

Hastings, Nebraska, 68901

Active Not Recruiting

Oncology Hematology West - Methodist

Omaha, Nebraska, 68114

Recruiting

Nebraska Methodist Hospital (change from Chi Health Bergan Mercy)

Omaha, Nebraska, 68124

Recruiting

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169

Withdrawn

Cancer Care & Hematology Specialists

Reno, Nevada, 89511

Withdrawn

Regional Cancer Care Associates LLC

East Brunswick, New Jersey, 08816

Recruiting

Hunterdon Medical Center

Flemington, New Jersey, 08822

Recruiting

Summit Medical Group, P.A.

Florham Park, New Jersey, 07932

Withdrawn

Rutgers Health

New Brunswick, New Jersey, 08901

Recruiting

Overlook Medical Center

Summit, New Jersey, 07901

Recruiting

University of New Mexico

Albuquerque, New Mexico, 87131

Recruiting

San Juan Oncology Associates

Farmington, New Mexico, 87401

Recruiting

New York Oncology Hematology (NYOH)

Amsterdam, New York, 12010

Withdrawn

Roswell Park Cancer Institute

Buffalo, New York, 14263

Withdrawn

Hematology Oncology Associates of Central New York, PC

East Syracuse, New York, 13057

Recruiting

Northwell Health

Lake Success, New York, 11042

Recruiting

Laura and Isaac Perlmutter Cancer Canter

New York, New York, 10016

Recruiting

Lipson Cancer Institute - Linden Oaks

Rochester, New York, 14618

Recruiting

New York Cancer and Blood Specialists

Shirley, New York, 11967

Recruiting

Stony Brook Medicine

Stony Brook, New York, 11794

Recruiting

SUNY Upstate Medical University

Syracuse, New York, 13210

Recruiting

Montefiore Medical Center

The Bronx, New York, 10467

Withdrawn

Clinical Research Alliance

Westbury, New York, 11590

Withdrawn

White Plains Hospital Physician Associates

White Plains, New York, 10601

Recruiting

Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27514

Recruiting

Duke Cancer Institute

Durham, North Carolina, 27710

Recruiting

Cone Health Medical Group (Moses Cone Health System)

Greensboro, North Carolina, 27403

Recruiting

East Carolina University Health Medical Center

Greenville, North Carolina, 27834

Withdrawn

FirstHealth Outpatient Cancer Center

Pinehurst, North Carolina, 28374

Withdrawn

UNC Rex Cancer Center

Raleigh, North Carolina, 27607

Withdrawn

UNC Nash Cancer Center

Rocky Mount, North Carolina, 27804

Withdrawn

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina, 27157

Recruiting

Good Samaritan Hospital

Cincinnati, Ohio, 45220

Recruiting

Oncology Hematology Care, Inc.

Cincinnati, Ohio, 45242

Recruiting

Ohio State University CRS

Columbus, Ohio, 43212

Recruiting

Ohio Health Research Institute

Columbus, Ohio, 43214

Recruiting

Columbus NCORP

Columbus, Ohio, 43215

Recruiting

Anita Stewart Oncology Center

Columbus, Ohio, 43221

Recruiting

Toledo Clinic Cancer Center

Toledo, Ohio, 43623

Not Yet Recruiting

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

Withdrawn

St. Charles Health System, Inc. DBA St. Charles Medical Center

Bend, Oregon, 97701

Recruiting

Samaritan Hospital

Corvallis, Oregon, 97330

Recruiting

Willamette Valley Cancer Institute and Research Center

Eugene, Oregon, 97401

Recruiting

Asante Rogue Regional Medical Center

Medford, Oregon, 97504

Withdrawn

Providence Cancer Institute - Oncology Clinical Trials

Portland, Oregon, 97213

Withdrawn

Oregon Health & Science University

Portland, Oregon, 97239

Recruiting

Saint Luke's University Hospital

Bethlehem, Pennsylvania, 18015

Withdrawn

Lancaster General Health

Lancaster, Pennsylvania, 17601

Recruiting

University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, 19104

Recruiting

UPMC Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213

Recruiting

Guthrie Clinical Research

Sayre, Pennsylvania, 18840

Recruiting

Reading Hospital and Medical Center

West Reading, Pennsylvania, 19611

Withdrawn

Lankenau Medical Center

Wynnewood, Pennsylvania, 19106

Recruiting

Cancer Care Associates of York

York, Pennsylvania, 17403

Recruiting

Providence Health

Providence, Rhode Island, 02905

Recruiting

Medical University of South Carolina

Charleston, South Carolina, 29425

Recruiting

Spartanburg Medical Center

Spartanburg, South Carolina, 29303

Recruiting

Monument Health Cancer Care Institute

Rapid City, South Dakota, 57701

Recruiting

Avera Cancer Institute

Sioux Falls, South Dakota, 57105

Recruiting

Ballad Health Cancer Care - Kingsport

Kingsport, Tennessee, 37660

Withdrawn

Center for Biomedical Research, LLC

Knoxville, Tennessee, 37909

Withdrawn

University of Tennessee

Knoxville, Tennessee, 37920

Recruiting

Hendrick Health System

Abilene, Texas, 79601

Withdrawn

Texas Oncology

Austin, Texas, 78731

Recruiting

Texas Oncology

El Paso, Texas, 79902

Recruiting

MD Anderson Cancer Center

Houston, Texas, 77030

Recruiting

Joe Arrington Cancer Research and Treatment Center

Lubbock, Texas, 79410

Withdrawn

Texas Oncology

San Antonio, Texas, 78240

Recruiting

Huntsman Cancer Institute

Salt Lake City, Utah, 84112

Recruiting

University of Virginia

Charlottesville, Virginia, 22908

Recruiting

Inova Fairfax Hospital

Fairfax, Virginia, 22031

Recruiting

Bon Secours Cancer Institute at St. Francis

Midlothian, Virginia, 23114

Recruiting

Virginia Commonwealth University Medical Center

Richmond, Virginia, 23298

Withdrawn

Oncology and Hematology Associates of Southwest Virginia, Inc

Wytheville, Virginia, 24382

Recruiting

Providence Regional Cancer System

Lacey, Washington, 98503

Recruiting

MultiCare Regional Cancer Center - Tacoma

Puyallup, Washington, 98372

Recruiting

Northwest Medical Specialties, PLLC

Puyallup, Washington, 98373

Recruiting

University of Washington

Renton, Washington, 98055

Withdrawn

Medical Oncology Associates

Spokane, Washington, 99208

Withdrawn

West Virginia University Hospital

Morgantown, West Virginia, 26505

Recruiting

ThedaCare Regional Cancer Center

Appleton, Wisconsin, 54911

Withdrawn

Ascension St. Francis Reiman Cancer Center

Franklin, Wisconsin, 53132

Recruiting

HSHS Saint Mary's Hospital Medical Center - Green Bay

Green Bay, Wisconsin, 54303

Withdrawn

University of Wisconsin

Madison, Wisconsin, 53792

Withdrawn

References

  • Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (+/- capecitabine) for residual triple-negative breast cancer. Future Oncol. 2024;20(31):2343-2355. doi: 10.1080/14796694.2024.2357534. Epub 2024 Jun 26.(PubMed)